$15.13
2.89% today
Nasdaq, May 09, 03:50 pm CET
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Edgewise Therapeutics Inc Stock price

$14.70
+3.21 27.94% 1M
-21.68 59.59% 6M
-12.00 44.94% YTD
-6.19 29.63% 1Y
+7.25 97.32% 3Y
-15.30 51.00% 5Y
-15.30 51.00% 10Y
Nasdaq, Closing price Thu, May 08 2025
+0.18 1.24%
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Key metrics

Market capitalization $1.55b
Enterprise Value $1.08b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.04
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-158.83m
Free Cash Flow (TTM) Free Cash Flow $-110.34m
Cash position $470.17m
EPS (TTM) EPS $-1.45
P/E forward negative
Short interest 17.09%
Show more

Is Edgewise Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.

Edgewise Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Edgewise Therapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Edgewise Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Edgewise Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.25 2.25
36% 36%
-
-2.25 -2.25
36% 36%
-
- Selling and Administrative Expenses 29 29
36% 36%
-
- Research and Development Expense 125 125
40% 40%
-
-157 -157
39% 39%
-
- Depreciation and Amortization 2.25 2.25
36% 36%
-
EBIT (Operating Income) EBIT -159 -159
39% 39%
-
Net Profit -134 -134
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edgewise Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edgewise Therapeutics Inc Stock News

Neutral
PRNewsWire
one day ago
– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – –  On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne...
Positive
The Motley Fool
7 days ago
On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compiled by S&P Global Market Intelligence, its share price vaulted nearly 14% higher across the week.
Negative
24/7 Wall Street
about one month ago
Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.
More Edgewise Therapeutics Inc News

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Head office United States
CEO Kevin Koch
Employees 110
Founded 2017
Website www.edgewisetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today